AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of oncology, cardiovascular, metabolic, respiratory, inflammation, autoimmune, infection, and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Oncology is a therapeutic area in which AstraZeneca has a deep-rooted heritage. Our vision is to help patients by redefining the cancer treatment paradigm and one day, eliminating cancer as cause of death. We are aiming to bring six new cancer medicines to patients by 2020.
Our broad pipeline of next-generation medicines is focused on four main disease areas—ovarian, lung, breast, and hematological cancers. These are being targeted through four key platforms—Immuno-Oncology, the genetic drivers of cancer and resistance, DNA damage repair, and antibody-drug conjugates.